Whitehawk Therapeutics, Inc. (WHWK) shareholders
Close on Nov 18, 2026Market cap $178.44MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Behzad Aghazadeh Joint filing with Avoro Capital Advisors LLC (19.99%) | 18,292,675 | 19.99% | 13D (active) amendment | May 12, 2026 |
| Fan Yu Joint filing with ABG Global Life Science Capital Partners V GP Limited (8.10%), ABG Global Life Science Capital Partners V GP, L.P. (8.10%) and 3 more | 5,679,253 | 9.40% | 13G (passive) amendment | Jun 30, 2026 |
| Anupam Dalal Joint filing with Acuta Capital Partners, LLC (8.70%), Acuta Capital Fund, LP (6.60%) | 4,843,775 | 9.00% | 13D (active) amendment | May 14, 2026 |
| Suvretta Capital Management, LLC Joint filing with Cowen Aaron (9.99%), Averill Master Fund, Ltd. (8.90%) | 4,727,510 | 9.99% | 13G (passive) | Mar 4, 2025 |
| OrbiMed Genesis GP LLC Joint filing with OrbiMed Advisors LLC (8.90%) | 4,166,000 | 8.90% | 13G (passive) | Mar 31, 2025 |
| OrbiMed Advisors LLC Joint filing with OrbiMed Genesis GP LLC (7.30%) | 3,934,296 | 7.30% | 13G (passive) amendment | Jun 30, 2026 |
| Coastlands Capital LLC Joint filing with Coastlands Capital LP (5.98%), Coastlands Capital Partners LP (5.98%) and 2 more | 2,819,215 | 5.98% | 13G (passive) | Aug 19, 2025 |
| QVT Financial LP | 2,313,702 | 9.37% | 13G (passive) | Dec 31, 2024 |
| Point72 Capital Advisors, Inc. Joint filing with Point72 Asset Management, L.P. (6.00%), Steven A. Cohen (6.00%) | 1,470,311 | 6.00% | 13G (passive) | Jan 22, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of WHWK | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Yu Fan | 4,861,314 | 8.53% | $22.26M | +2,791,314 | 20.63% |
| Acuta Capital Partners, LLC | 4,685,912 | 8.22% | $21.46M | +1,275,510 | 14.96% |
| QVT Financial LP | 4,615,709 | 8.10% | $21.14M | – | 1.27% |
| Suvretta Capital Management, LLC | 4,300,000 | 7.54% | $19.69M | +600,000 | 0.36% |
| Orbimed Advisors LLC | 3,934,296 | 6.90% | $18.02M | −231,704 | 0.33% |
| Avoro Capital Advisors LLC | 2,849,402 | 5.00% | $13.05M | – | 0.12% |
| Siren, L.L.C. | 2,337,102 | 4.10% | $10.70M | +255,102 | 0.22% |
| KVP Capital Advisors, LP | 2,165,997 | 3.80% | $9.92M | – | 7.28% |
| BlackRock, Inc. | 1,922,828 | 3.37% | $8.81M | +1,571,443 | 0.00% |
| Vanguard Capital Management LLC | 1,388,561 | 2.44% | $6.36M | +72,791 | 0.00% |
| ADAR1 Capital Management, LLC | 1,341,394 | 2.35% | $6.14M | +1,212,891 | 0.28% |
| Acorn Capital Advisors, LLC | 1,139,363 | 2.00% | $5.22M | – | 1.42% |
| Stempoint Capital LP | 1,021,037 | 1.79% | $4.68M | −857,701 | 0.81% |
| Geode Capital Management, LLC | 899,780 | 1.58% | $4.12M | +442,240 | 0.00% |
| Ally Bridge Group (NY) LLC | 817,939 | 1.43% | $3.75M | – | 3.31% |
| Woodline Partners LP | 436,614 | 0.77% | $2.00M | +155,117 | 0.01% |
| Renaissance Technologies LLC | 413,822 | 0.73% | $1.90M | −14,800 | 0.00% |
| State Street Corp | 386,982 | 0.68% | $1.77M | +226,600 | 0.00% |
| Millennium Management LLC | 380,406 | 0.67% | $1.74M | +70,732 | 0.00% |
| Eversept Partners, LP | 303,306 | 0.53% | $1.39M | −3,494 | 0.07% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 78 | 43M | 75.8% | 29 / 29 | 11 / 12 | 10M | 2M |
| Q1 2026 | 62 | 35M | 61.7% | 21 / 16 | 7 / 6 | 4M | 0M |
| Q4 2025 | 48 | 33M | 57.8% | 12 / 10 | 6 / 5 | 5M | 1M |
| Q3 2025 | 41 | 29M | 50.6% | 5 / 6 | 10 / 3 | 1M | 1M |
| Q2 2025 | 39 | 29M | 51.6% | 2 / 9 | 11 / 13 | 1M | 3M |
| Q1 2025 | 50 | 32M | 55.8% | 9 / 13 | 16 / 11 | 18M | 1M |
| Q4 2024 | 53 | 15M | 26.3% | 8 / 12 | 16 / 7 | 5M | 2M |
| Q3 2024 | 52 | 12M | 21.0% | 10 / 7 | 22 / 22 | 4M | 4M |
| Q2 2024 | 65 | 11M | 20.1% | 21 / 14 | 22 / 16 | 1M | 4M |
| Q1 2024 | 60 | 14M | 24.8% | 9 / 18 | 16 / 13 | 2M | 1M |
| Q4 2023 | 65 | 13M | 23.3% | 12 / 26 | 11 / 19 | 2M | 3M |
| Q3 2023 | 73 | 15M | 25.8% | 12 / 25 | 15 / 6 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
47 funds held WHWK in Q2 2026, 75% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of WHWK | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 887,972 | 1.56% | $4.07M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 734,137 | 1.29% | $3.36M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 470,854 | 0.83% | $2.16M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 352,173 | 0.62% | $1.36M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 281,712 | 0.49% | $1.29M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 192,391 | 0.34% | $908.09K | 0.00% | May 31, 2026 |
| Ultra-Small Company Fund | 165,284 | 0.29% | $757.00K | 0.77% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 110,575 | 0.19% | $506.43K | 0.03% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 78,832 | 0.14% | $303.50K | 0.00% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 62,161 | 0.11% | $293.40K | 0.00% | May 31, 2026 |
| Master Small Cap Index Series | 60,657 | 0.11% | $277.81K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 57,711 | 0.10% | $272.40K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 46,572 | 0.08% | $219.82K | 0.00% | May 31, 2026 |
| Fidelity Small Cap Value Index Fund | 45,075 | 0.08% | $206.44K | 0.01% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 43,799 | 0.08% | $168.63K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David James Lennon | CHIEF EXECUTIVE OFFICER, Director | 569,643 | 1.00% | Sep 18, 2026 |
| David Dornan | Chief Scientific Officer | – | – | Sep 18, 2026 |
| Scott M. Giacobello | CHIEF FINANCIAL OFFICER | 333,489 | 0.58% | Sep 18, 2026 |
| Margaret Dugan | Chief Medical Officer | 19,132 | 0.03% | Sep 18, 2026 |
| Bryan Ball | See remarks | 448,126 | 0.79% | Sep 18, 2026 |
| Vijay K. Iyengar | Director | – | – | Sep 11, 2026 |
| Anupam Dalal | Director | 4,687,042 | 8.22% | Jul 30, 2026 |
| Behzad Aghazadeh | Director, 10% owner | 2,211,752 | 3.88% | Jun 15, 2026 |
| Capital Advisors LLC Avoro | Director, 10% owner | – | – | Jun 15, 2026 |
| Ventures LLC Avoro | Director, 10% owner | 3,471,752 | 6.09% | Jun 15, 2026 |
| Richard E. Maroun | Director | – | – | Jun 15, 2026 |
| Caley Castelein | Director | 2,440,794 | 4.28% | Jun 15, 2026 |
| Emma Reeve | Director | – | – | Jun 15, 2026 |
| Neil Desai | Director | 1,171,543 | 2.06% | Jun 15, 2026 |
| Mohammad Hirmand | Director | – | – | Jun 15, 2026 |
| Baiteng Zhao | Director | 1,250,000 | 2.19% | Jun 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Anupam Dalal Director | May 14, 2026 | Award | +1,275,510 | $3.92 | $5.00M | 4,685,912 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | May 14, 2026 | Award | +51,021 | $3.92 | $200.00K | 569,643 |
| Margaret Dugan Chief Medical Officer | May 14, 2026 | Award | +19,132 | $3.92 | $75.00K | 19,132 |
| Bryan Ball See remarks | May 14, 2026 | Award | +51,020 | $3.92 | $200.00K | 448,126 |
| Caley Castelein Director | May 14, 2026 | Award | +255,102 | $3.92 | $1,000.00K | 274,796 |
| Scott M. Giacobello CHIEF FINANCIAL OFFICER | May 14, 2026 | Award | +38,265 | $3.92 | $150.00K | 333,489 |
| Scott M. Giacobello CHIEF FINANCIAL OFFICER | Apr 16, 2026 | Sale | −141,600 | $4.13 | $584.81K | 295,224 |
| Scott M. Giacobello CHIEF FINANCIAL OFFICER | Apr 15, 2026 | Sale | −77,000 | $3.86 | $297.22K | 436,824 |
| Bryan Ball See remarks | Apr 14, 2026 | Sale | −92,460 | $3.64 | $336.55K | 397,106 |
| Bryan Ball See remarks | Apr 13, 2026 | Sale | −26,389 | $3.46 | $91.31K | 489,566 |
| Bryan Ball See remarks | Apr 10, 2026 | Sale | −6,596 | $3.43 | $22.62K | 515,955 |
| Bryan Ball See remarks | Apr 9, 2026 | Sale | −50,000 | $3.57 | $178.50K | 522,551 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Apr 9, 2026 | Sale | −14,500 | $3.38 | $49.01K | 518,622 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Apr 8, 2026 | Sale | −63,945 | $3.40 | $217.41K | 533,122 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Apr 7, 2026 | Sale | −94,087 | $3.43 | $322.72K | 597,067 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Apr 6, 2026 | Sale | −102,395 | $3.51 | $359.41K | 691,154 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Apr 2, 2026 | Sale | −26,858 | $3.48 | $93.47K | 793,549 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Apr 1, 2026 | Option exercise | +775,828 | – | – | 820,407 |
| Scott M. Giacobello CHIEF FINANCIAL OFFICER | Apr 1, 2026 | Option exercise | +473,902 | – | – | 502,002 |
| Bryan Ball See remarks | Apr 1, 2026 | Option exercise | +366,532 | – | – | 572,551 |
| Scott M. Giacobello CHIEF FINANCIAL OFFICER | Mar 2, 2026 | Sale | −2,594 | $3.31 | $8.59K | 28,100 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Mar 2, 2026 | Sale | −5,100 | $3.31 | $16.88K | 44,579 |
| Bryan Ball See remarks | Mar 2, 2026 | Sale | −1,834 | $3.31 | $6.07K | 206,019 |
| Scott M. Giacobello CHIEF FINANCIAL OFFICER | Mar 1, 2026 | Option exercise | +6,750 | – | – | 30,694 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Mar 1, 2026 | Option exercise | +16,250 | – | – | 49,679 |
| Bryan Ball See remarks | Mar 1, 2026 | Option exercise | +5,000 | – | – | 207,853 |
| Anupam Dalal Director | Mar 4, 2025 | Award | +1,561,000 | $2.40 | $3.75M | 3,410,402 |
| Bryan Ball See remarks | Mar 4, 2025 | Award | +100,000 | $2.40 | $240.00K | 202,853 |
| Caley Castelein Director | Mar 4, 2025 | Award | +1,666,000 | $2.40 | $4.00M | 2,165,998 |
| Baiteng Zhao Director | Mar 4, 2025 | Award | +1,250,000 | $2.40 | $3.00M | 1,250,000 |
| Bryan Ball See remarks | Mar 3, 2025 | Sale | −2,147 | $2.35 | $5.05K | 102,853 |
| Scott M. Giacobello CHIEF FINANCIAL OFFICER | Mar 3, 2025 | Sale | −2,806 | $2.35 | $6.59K | 23,944 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Mar 3, 2025 | Sale | −5,690 | $2.35 | $13.37K | 33,429 |
| Bryan Ball See remarks | Mar 1, 2025 | Option exercise | +5,000 | – | – | 105,000 |
| Scott M. Giacobello CHIEF FINANCIAL OFFICER | Mar 1, 2025 | Option exercise | +6,750 | – | – | 26,750 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Mar 1, 2025 | Option exercise | +16,250 | – | – | 39,119 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Oct 3, 2024 | Sale | −9,689 | $1.94 | $18.80K | 22,869 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Oct 2, 2024 | Option exercise | +32,558 | – | – | 32,558 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Sep 3, 2024 | Sale(10b5-1 plan) | −40,000 | $1.71 | $68.40K | 1,171,543 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Aug 5, 2024 | Sale(10b5-1 plan) | −5,652 | $1.34 | $7.57K | 1,211,543 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Aug 2, 2024 | Sale(10b5-1 plan) | −18,933 | $1.41 | $26.70K | 1,217,195 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Aug 1, 2024 | Sale(10b5-1 plan) | −15,415 | $1.50 | $23.12K | 1,236,128 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Jul 2, 2024 | Sale(10b5-1 plan) | −8,652 | $1.34 | $11.59K | 1,251,543 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Jul 1, 2024 | Sale(10b5-1 plan) | −31,348 | $1.45 | $45.45K | 1,260,195 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Jun 4, 2024 | Sale(10b5-1 plan) | −20,225 | $1.77 | $35.80K | 1,291,543 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Jun 3, 2024 | Sale(10b5-1 plan) | −19,775 | $1.81 | $35.79K | 1,311,768 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | May 1, 2024 | Sale(10b5-1 plan) | −40,000 | $1.93 | $77.20K | 1,331,543 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Apr 2, 2024 | Sale(10b5-1 plan) | −22,228 | $2.23 | $49.57K | 1,371,543 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Apr 1, 2024 | Sale(10b5-1 plan) | −17,772 | $2.31 | $41.05K | 1,393,771 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Mar 4, 2024 | Sale(10b5-1 plan) | −14,964 | $2.10 | $31.42K | 1,411,543 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Mar 1, 2024 | Sale(10b5-1 plan) | −27,036 | $1.97 | $53.26K | 1,426,507 |
| Neil Desai Executive Chairman, Director | Feb 1, 2024 | Sale(10b5-1 plan) | −42,000 | $1.74 | $73.08K | 1,453,543 |
| Neil Desai Executive Chairman, Director | Jan 2, 2024 | Sale(10b5-1 plan) | −42,000 | $2.06 | $86.52K | 1,495,543 |
| Neil Desai Executive Chairman, Director | Dec 6, 2023 | Sale(10b5-1 plan) | −7,037 | $4.82 | $33.92K | 1,537,543 |
| Neil Desai Executive Chairman, Director | Dec 5, 2023 | Sale(10b5-1 plan) | −15,740 | $5.02 | $79.01K | 1,544,580 |
| Neil Desai Executive Chairman, Director | Dec 4, 2023 | Sale(10b5-1 plan) | −10,876 | $5.15 | $56.01K | 1,560,320 |
| Neil Desai Executive Chairman, Director | Dec 1, 2023 | Sale(10b5-1 plan) | −8,347 | $5.14 | $42.90K | 1,571,196 |
| Neil Desai Executive Chairman, Director | Nov 2, 2023 | Sale(10b5-1 plan) | −31,662 | $4.46 | $141.21K | 1,579,543 |
| Neil Desai Executive Chairman, Director | Nov 1, 2023 | Sale(10b5-1 plan) | −10,338 | $4.32 | $44.66K | 1,611,205 |
| Neil Desai Executive Chairman, Director | Oct 3, 2023 | Sale(10b5-1 plan) | −16,431 | $4.10 | $67.37K | 1,621,543 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Whitehawk Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,345 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Scott M. Giacobello Officer | Apr 15, 2026 | 233,766 | $900.00K | Apr 15, 2026 | Restricted Stock Units |
| David James Lennon Officer, Director | Apr 9, 2026 | 4,364 | $14.75K | Apr 9, 2026 | Restricted Stock Units |
| Bryan Ball Officer | Apr 9, 2026 | 196,969 | $650.00K | Apr 9, 2026 | Restricted Stock Units |
| David James Lennon Officer, Director | Apr 2, 2026 | 297,421 | $1.03M | Apr 2, 2026 | Restricted Stock Units |
| Scott M. Giacobello Officer | Mar 3, 2025 | 2,806 | $6.59K | Mar 3, 2025 | Restricted Stock Units |
| David James Lennon Officer, Director | Mar 3, 2025 | 5,690 | $13.37K | Mar 3, 2025 | Restricted Stock Units |
| Bryan Ball Officer | Mar 3, 2025 | 2,147 | $5.05K | Mar 3, 2025 | Restricted Stock Units |
| David James Lennon Officer, Director | Oct 3, 2024 | 9,689 | $18.80K | Oct 3, 2024 | Restricted Stock Units |
| Neil Desai Officer | Sep 3, 2024 | 120,000 | $214.42K | Sep 3, 2024 | Share Conversion |
| Neil Desai Officer | Jun 3, 2024 | 120,000 | $220.00K | Jun 3, 2024 | Share Conversion |
| Neil Desai Officer | Mar 1, 2024 | 122,000 | $241.12K | Mar 1, 2024 | Share Conversion |
| Neil Desai Officer | Dec 1, 2023 | 126,000 | $668.43K | Dec 1, 2023 | Share Conversion |
| Neil Desai Officer | Sep 1, 2023 | 126,000 | $787.68K | Sep 1, 2023 | Share Conversion |
| Neil Desai Officer | Jul 3, 2023 | 84,000 | $574.56K | Jul 3, 2023 | Share Conversion |
| Neil Desai Officer | Apr 3, 2023 | 126,000 | $932.72K | Apr 3, 2023 | Share Conversion |
See a number that looks wrong?